167.50 0.00 (0.00%)
After hours: 4:45PM EST
|Bid||0.00 x 1000|
|Ask||0.00 x 3200|
|Day's Range||166.99 - 170.53|
|52 Week Range||147.70 - 190.36|
|Beta (3Y Monthly)||1.13|
|PE Ratio (TTM)||13.27|
|Earnings Date||Feb 4, 2019 - Feb 8, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||187.71|
LabCorp will remain the exclusive in-network clinical laboratory for the nearly 900,000 Medicaid members of Horizon Blue Cross Blue Shield of New Jersey (Horizon BCBSNJ). LabCorp will continue as a preferred provider of laboratory services to all other Horizon BCBSNJ members. Horizon Blue Cross Blue Shield of New Jersey (Horizon BCBSNJ) and LabCorp® (LH) have renewed their long-standing strategic relationship to provide comprehensive clinical laboratory services for the more than 3.8 million people enrolled in Horizon BCBSNJ health plans.
A major Triad developer has sold a local industrial property portfolio for approximately $81.6 million. Samet Corp. and family members sold six properties in N.C. Industrial Center in Mebane and one property in Riverbend Industrial Park in Graham, totaling about 1.
LabCorp® (LH), a leading global life sciences company, today announced the launch of Pixel by LabCorp℠, the latest innovation in the company’s strategy to create a leading and differentiated consumer experience. Pixel by LabCorp enhances patient convenience by offering consumer-initiated wellness testing featuring sample self-collection anytime and anywhere, and personalized online results. “Consumers are focusing on monitoring and improving their health and wellness, rather than reacting to symptoms of disease.
NEW YORK, Oct. 30, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
LabCorp® (LH), a leading global life sciences company that is deeply integrated in guiding patient care, today announced it now supports Health Records on iPhone®. This feature will make it easy for LabCorp patients to access their LabCorp laboratory test results, along with other available medical data from multiple providers, whenever they choose. LabCorp test results are viewable in the Apple® Health app for LabCorp patients who have a LabCorp Patient™ account and enable integration with the Health Records app.
Within LabCorp (LH) Diagnostics business the disposition of certain businesses and the implementation of the Protecting Access to Medicare Act (PAMA) dented growth.
One of the best investments we can make is in our own knowledge and skill set. With that in mind, this article will work through how we can use Return Read More...
LabCorp (LH) delivered earnings and revenue surprises of -4.53% and -0.39%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Burlington, North Carolina-based company said it had net income of $3.10. Earnings, adjusted for one-time gains and costs, were $2.74 per share. The results did not meet Wall ...
BURLINGTON, N.C.-- -- Q3 revenue of $2.8 billion, up 8% over $2.6 billion last year Q3 diluted EPS of $3.10, which includes the net gain on the disposition of businesses of $1.22 per share Q3 adjusted EPS of $2.74, which was negatively impacted by approximately $0.10 per share from the ransomware attack and Hurricane Florence 2018 adjusted EPS guidance of $11.25 to $11.45, up 22% to 24% over 2017, ...
Long-term potential of the Medical Products industry appears promising at the moment amid certain short-term geopolitical insecurities.
LabCorp (LH) might sustain its winning streak in third-quarter 2018 after having retained the same for the past few quarters. However, reimbursement pressure remains a concern.
LabCorp’s Expertise in Health System Collaborations will Benefit Patients across Kentucky, Southern Indiana
LabCorp® (LH), a leading global life sciences company, and Definiens®, a pioneer in artificial intelligence (AI) based image analysis, announced a strategic collaboration to improve global development of precision medicine. The collaboration, between Definiens and LabCorp’s Covance drug development business, will enable seamless integration of digital pathology with clinical-trial design and tissue-based testing solutions, resulting in a faster and more rigorous approach to biomarker validation and companion diagnostic co-development.
The North Carolina Biotechnology Center, City of Burlington, LabCorp, Alamance Community College and Illumina will partner to train local talent for new bioscience jobs